Interferon Treatment of Multiple Sclerosis
Azra Alajbegovic, Dervis Deljo, Salem Alajbegovic, Jasminka Djelilovic-Vranic, Ljubica Todorovic, Merita Tiric-Campara
Mat Soc Med. 2012; 24(1): 38-43
Introduction: In the treatment of Multiple Sclerosis (MS) differ: treatment of relapse, treatment slow the progression of the disease (immunomodulators and immunosuppression), and symptomatic treatment. The aim of this study is to analyze the application of interferon therapy in the treatment of MS-E: Process the disease, patients with multiple sclerosis who have passed the commission for multiple sclerosis at the Neurology Clinic of Clinical Center of Sarajevo University as a reference center for referral to the Commission for multiple sclerosis from the Federal Ministry of Health in 2009 year in terms of total number examined, gender differences, diagnostic tests (MRI, CSF, EP), neurological findings and EDSS scores. Provide a section through the continuous support and education of patients during the introduction Betaferon in therapy with the goal of education for self-use and reduce the incidence of side effects of interferon therapy. Materials and methods: The material for the work they were histories of patients who are registered as patients who have undergone a commission for MS at Department of Neurology, University Clinical Center in Sarajevo. The evaluation was retrospective. It was used a specially designed form, which is usually applied to patients referred to this committee. After the collected material was carried out data processing. The study comprised 34 patients who have undergone a commission of which 16 patients received interferon therapy. Results: In 2009 at the Neurology Clinic CCUS have treated 34 patients who passed the committee for recommendation to interferon therapy (25 women and 9 men). The diagnosis of multiple sclerosis is safe based on the criteria of international panel in 2000. EDSS Average score for men was 1.8, 1.9 for women, the total EDSS score was 1.8. The gender ratio is 3:1 in women than in men. Sixteen patients received interferon by the Commission for multiple sclerosis, the Federal Ministry of Health and their therapy was initiated at the clinic. Conclusion: For the period of 2009, a total of 34 patients were examined with multiple sclerosis who received interferon treatment recommendations at the expense of the Federal Solidarity Fund at the Neurology Clinic CCUS Sarajevo. The average EDSS score was 1.8. There were no significant differences in neurological findings between patients who were previously treated with interferon and patients who were waiting for treatment.
1. Azra Kurtović-Alajbegović i saradnici:MULTIPLA SKLEROZA. Magistrat Sarajevo, Sarajevo decembar 2005.
2. Kantardžić Dželaludin i saradnici:Klinička neurologija. Svjetlost, Sarajevo 2001.
3. Multiple sclerosis: Hope through research. National Institute of Neurological Disorders and Stroke. http://www.ninds.nih.gov/disorders/multiple_sclerosis/detail_multiple_sclerosis.htm. Accessed Oct. 1, 2008.
4. Olek MJ. Epidemiology, risk factors and clinical features of multiple sclerosis in adults. http://www.uptodate.com/home/index.html. Accessed Oct. 1, 2008.
5. Noseworthy JH, et al. Multiple sclerosis. In: Goetz CG, et al. Textbook of Clinical Neurology. 3rd ed. Philadelphia, Pa.: Saunders Elsevier; 2007. http://www.mdconsult.com/das/book/body/106141078-3/0/1488/405.html#4-u1.0-B978-1-4160-3618-0..10048-7-s0030_4069. Accessed Oct. 1, 2008.
6. Fatigue. National Multiple Sclerosis Society. http://www.nationalmssociety.org/about-multiple-sclerosis/symptoms/fatigue/index.aspx. Accessed Oct. 2, 2008.
7. Olek MJ. Diagnosis of multiple sclerosis in adults. http://www.uptodate.com/home/index.html. Accessed Oct. 2, 2008.
8. Neurological diagnostic tests and procedures. National Institute of Neurological Disorders and Stroke. http://www.ninds.nih.gov/disorders/misc/diagnostic_tests.htm. Accessed Oct. 1, 2008.
9. You can … maintain good nutrition. National Multiple Sclerosis Society. http://www.nationalmssociety.org/living-with-multiple-sclerosis/you-can/maintain-good-nutrition/index.aspx. Accessed Oct. 2, 2008.
10. Van Bockstael, S Gosselin,S.Vukusic,C Confavreux. Prevalence of Multiple Sclerosis in Franch farmers: a notionwide survey.Multiple Sclerosis Volumen 10.Suplement 2, September 2004: 156.
11. Hooshmand F, Jangouk R. study of 1714 Iranian multiple sclerosis patients.Multiple sclerosis Vol.10 (suppl2):september 2004.157.
12. Đelilović J, Alajbegović A,Suljić E et al. Multiple sclerosis at the Neurological Clinic in Sarajevo before and after the war,1.Internacionalna konferencija o multiploj sklerozi u Dubrovniku,Neurol.Croat. 2001, Vol.50,Suplement,(1):40.
13. Duquette P et al. Multiple sclerosis in childhood:clinical profile in 125 patientsJournal of Pediatric,1997,111:359-363.
14. A.Guseo. 66 years of multiple sclerosis in Feje’r country, West Hungary. Multiple Sclerosis Vol.10 (2) September 2004:156.
15. Alajbegović i saradnici. Tretman multiple skleroze viskim dozama kortikosterida na Neurološkoj klinici KCU Sarajevo.Simpozijum o MS Varaždinske Toplice 3004.Zbornik radova 23-28.
16. Sepčić J et al. Multiple sclerosis cluster in Gorski Kotar,Croatia,Yugoslavia, In: Battaglia Med. Multiple sclerosis research.1989,Amsterdam,Elsevier:165-169.
17. Sepčić J et al. Nutritional factors and multiple sclerosis in Gorski Kotar, Croatia, Neuroepidemiology,1993,12:234-240.
18. Poser CM,Paty DW, Scheinberg L et alt. New diagnostic criteria for multiple sclerosis: guidelines for research protocols.Ann Neurol 1983;13:227-231.
19. Durelli,L. Verdun E, Barbero P. et al.(2002)Every-other day interferon beta-1b versus oce-weekly interferon beta.1a for multiple sclertosis: Results of a 2-year prospective randomised multi-center study(INCOMIN).The Lancet 359,1453-60
20. IFNB Multipler Sclerosis Study Group(2003) Interferon -1b is effective in relapsing-remitting multiple sclerosis.I. Clinical results of a multicenter, randomized, double-blind, placebo controlled trial. Neurology 43, 655-66
21. Jacobs LD, Beck RW, Simon JH, et al, and the CHAMPS Study Group. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000 Sep 28;343:898–904.